Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2017.5332
Abstract: Importance Longitudinal circulating tumor DNA (ctDNA) has been shown to predict response and survival in patients with metastatic melanoma treated with anti–programmed cell death 1 (PD-1) antibodies. Pseudoprogression, defined as radiologic finding of disease progression… read more here.
Keywords: ctdna; response; ctdna profile; disease ... See more keywords
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2025 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2025.5144
Abstract: Importance Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer. While randomized clinical trials have not shown benefit across all patients, these… read more here.
Keywords: stage iii; cancer; analysis; ctdna ... See more keywords
Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations.
Sign Up to like & getrecommendations! Published in 2021 at "Molecular oncology"
DOI: 10.1002/1878-0261.13102
Abstract: Chondrosarcoma (CS) is a rare tumour type and the most common primary malignant bone cancer in adults. The prognosis, currently based on tumour grade, imaging and anatomical location, is not reliable and more objective biomarkers… read more here.
Keywords: chondrosarcoma; ctdna; tumour dna; circulating tumour ... See more keywords
Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular oncology"
DOI: 10.1002/1878-0261.13178
Abstract: Failure of colorectal cancer (CRC) treatment is due to residual disease, and its timely identification is critical for patient survival. Detecting CRC-associated mutations in patient circulating cell-free DNA is confounded by tumor mutation heterogeneity, requiring… read more here.
Keywords: tumor; tumor burden; treatment; bcat1 ikzf1 ... See more keywords
Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13357
Abstract: Brain metastasis (BM) genetically diverges from the primary tumor in non‐small‐cell lung cancer (NSCLC). Hence, accurately capturing clinically relevant alterations is pivotal for the delivery of targeted therapies. Circulating tumor DNA (ctDNA) sequencing has emerged… read more here.
Keywords: ctdna; plasma ctdna; brain; tumor ... See more keywords
Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13387
Abstract: Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be… read more here.
Keywords: resectable lung; lung cancer; ctdna; lung ... See more keywords
ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes.
Sign Up to like & getrecommendations! Published in 2023 at "Molecular oncology"
DOI: 10.1002/1878-0261.13416
Abstract: Taselisib is a potent β-sparing phosphatidylinositol 3-kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with response to PI3K inhibition,… read more here.
Keywords: treated taselisib; ctdna; advanced breast; taselisib fulvestrant ... See more keywords
Engineered crRNA Drives RPA‐T7‐CRISPR/Cas14a Cascade for Ultrasensitive Detection of ctDNA PIK3CA H1047R
Sign Up to like & getrecommendations! Published in 2025 at "Advanced Science"
DOI: 10.1002/advs.202507126
Abstract: The early detection of circulating tumor DNA (ctDNA) at mutant allele frequencies below 0.1% remains a critical challenge, significantly impeding therapeutic decision‐making. To address this limitation, TIDE‐Cas14a—an innovative CRISPR/Cas14a‐based duplex detection system is developed that… read more here.
Keywords: detection; crispr cas14a; cas14a; pik3ca h1047r ... See more keywords
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3087
Abstract: Circulating tumor DNA (ctDNA) has become the most investigated analyte in blood. It is shed from the tumor into the circulation and represents a subset of the total cell‐free DNA (cfDNA) pool released into the… read more here.
Keywords: cell; dna; ctdna; hematologic malignancies ... See more keywords
ANALYSIS OF CIRCULATING TUMOR DNA (ctDNA) IN CEREBROSPINAL FLUID DETECTS THE PRESENCE OF CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN B‐CELL LYMPHOMAS
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.3_2630
Abstract: (50%) of available biopsy and ctDNA samples respectively. Concordance between genetic profiles of biopsy and ctDNA was accurate for 22/30 patients (73.3%). Mutations of NFKBIE, TNFAIP3, STAT6, PTPN1, B2M, XPO1, ITPKB, GNA13 and SOCS1were found… read more here.
Keywords: ctdna; presence; analysis circulating; circulating tumor ... See more keywords
Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients
Sign Up to like & getrecommendations! Published in 2017 at "International Journal of Cancer"
DOI: 10.1002/ijc.30650
Abstract: Cell‐free circulating tumor DNA (ctDNA) in plasma has been used as a potential noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical implications of ctDNA detection in patients with metastatic pancreatic… read more here.
Keywords: metastatic pancreatic; ctdna; treatment; pancreatic cancer ... See more keywords